Exosomal hsa-miR-335-5p and hsa-miR-483-5p are novel biomarkers for rheumatoid arthritis: A development and validation study

Yu, Yeuni; Park, Sunhee; Lee, Hansong; Kwon, Eun Jung; Park, Hae Ryoun; Kim, Yun Hak; Lee, Seung-Geun

doi:10.1016/j.intimp.2023.110286

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A common target of these exosomal miRNAs, the SRSF4 has marked a decrease in synovial fluid, suggesting that along with miR-335-5p and miR-483-5p, they could be promising disease biomarkers. 10 Other exosomal biomarkers, found in the serum of RA patients of a pilot study, were the exomiR-451a and exomiR-25-3p which along with the sTWEAK protein, correctly classified 95.6% of patients in the early disease stage. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is an inflammatory cytokine involved in the pathogenesis of RA, specifically FLSs proliferation, bone erosion and cytokine production, through signal transducer receptor Fn14 binding.…”

Section: Therapeutic and Diagnostic Potential Of Evsmentioning

confidence: 93%

“…The expression of this gene was decreased suggesting a potential implication in RA pathophysiology, ie blockage of cartilage repair. 10 Further investigation of the SRSF4 protein action is, however, required. Involved in cartilage repair is also miR-23a-3p specifically by suppression of PTEN and activation of the Akt signaling pathway in chondrocytes.…”

Section: Extracellular Vesicles and Exosomes In The Pathophysiology O...mentioning

confidence: 99%

“…Notably, EVs have been shown to participate in the pathophysiology of RA and may constitute an important factor in disease development and progression. 10–12 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis

Gavriilidi,

Wielińska,

Bogunia-Kubik

2024

JIR

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an incurable autoimmune disease with high morbidity and socioeconomic burden. Advances in therapeutics have improved patients’ quality of life, however due to the complex disease pathophysiology and heterogeneity, 30% of patients do not respond to treatment. Understanding how different genetic and environmental factors contribute to disease initiation and development as well as uncovering the interactions of immune components is key to the implementation of effective and safe therapies. Recently, the role of extracellular vesicles (EVs) in RA development and possible treatment has been an area of interest. EVs are small lipid-bound entities, often containing genetic material, proteins, lipids and amino acids, facilitating paracrine intercellular communication. They are secreted by all cells, and it is believed that they possess regulatory functions due to high complexity and functional diversity. Although it has been shown that EVs participate in RA pathophysiology, through immune modulation, their exact role remains elusive. Furthermore, EVs could be a promising therapeutic agent in various diseases including RA, due to their biocompatibility, low toxicity and possible manipulation, but further research is required in this area. This review provides a comprehensive discussion of disease pathophysiology and summarizes the latest knowledge regarding the role and therapeutic potential of EVs in RA.

show abstract

Section: Therapeutic and Diagnostic Potential Of Evsmentioning

confidence: 93%

Section: Extracellular Vesicles and Exosomes In The Pathophysiology O...mentioning

confidence: 99%

See 1 more Smart Citation

Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis

Gavriilidi,

Wielińska,

Bogunia-Kubik

2024

JIR

View full text Add to dashboard Cite

show abstract

“…In recent years, various extracellular vesicle‐related biomarkers have been developed for RA. Among circulating exosomes, miR‐335‐5p, miR‐486‐5p, SRSF4, 254 miR‐25‐3p, 255 , 256 and DPYSL3 and PSME1 proteins 257 can be used for early diagnosis. Exosomal lncRNAs have also been extensively studied in RA due to their advantages in regulating gene expression.…”

Section: Exosome Biomarkersmentioning

confidence: 99%

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases

Xu,

Jiang,

et al. 2024

MedComm

View full text Add to dashboard Cite

Exosomes are nanoscale vesicles of cellular origin. One of the main characteristics of exosomes is their ability to carry a wide range of biomolecules from their parental cells, which are important mediators of intercellular communication and play an important role in physiological and pathological processes. Exosomes have the advantages of biocompatibility, low immunogenicity, and wide biodistribution. As researchers’ understanding of exosomes has increased, various strategies have been proposed for their use in diagnosing and treating diseases. Here, we provide an overview of the biogenesis and composition of exosomes, describe the relationship between exosomes and disease progression, and focus on the use of exosomes as biomarkers for early screening, disease monitoring, and guiding therapy in refractory diseases such as tumors and neurodegenerative diseases. We also summarize the current applications of exosomes, especially engineered exosomes, for efficient drug delivery, targeted therapies, gene therapies, and immune vaccines. Finally, the current challenges and potential research directions for the clinical application of exosomes are also discussed. In conclusion, exosomes, as an emerging molecule that can be used in the diagnosis and treatment of diseases, combined with multidisciplinary innovative solutions, will play an important role in clinical applications.

show abstract

“…The inclusion of miRNAs in sEVs confers protection against enzymatic degradation in bodily uids, enabling them to reach target cells and exert robust biological regulatory effects [18]. Notably, certain miRNAs carried by sEVs have been implicated in the regulation of the synovial microenvironment in RA, emphasizing their capacity to mediate stable communications and modulate the RA state [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Macrophage-Derived miR-100-5p Orchestrates Synovial Proliferation and Inflammation in Rheumatoid Arthritis through mTOR Signaling

Liu,

Chen,

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation, causing substantial disability and reducing life quality. While macrophages are widely appreciated as a master regulator in the inflammatory response of RA, the precise mechanisms underlying the regulation of proliferation and inflammation in RA-derived fibroblast-like synoviocytes (RA-FLS) remain elusive. Here, we provide extensive evidence to demonstrate that macrophage contributes to RA microenvironment remodeling by extracellular vesicles (sEVs) and downstream miR-100-5p/ mammalian target of rapamycin (mTOR) axis. Results We showed that cBMDM-sEVs exhibited a notable increase in abundance compared with nBMDM-sEVs. cBMDM-sEVs induced significant RA-FLS proliferation and potent inflammatory responses. Mechanistically, decreased levels of miR-100-5p were detected in cBMDM-sEVs compared with nBMDM-sEVs. miR-100-5p overexpression ameliorated RA-FLS proliferation and inflammation by targeting the mTOR pathway. Partial attenuation of the inflammatory effects induced by cBMDM-sEVs on RA-FLS was achieved through the introduction of an overexpression of miR-100-5p. Conclusions Our work reveals the critical role of macrophages in exacerbating RA by facilitating the transfer of miR-100-5p-deficient sEVs to RA-FLS, and sheds light on novel disease mechanisms and provides potential therapeutic targets for RA interventions.

show abstract

Exosomal hsa-miR-335-5p and hsa-miR-483-5p are novel biomarkers for rheumatoid arthritis: A development and validation study

Cited by 9 publications

References 30 publications

Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis

Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases

Macrophage-Derived miR-100-5p Orchestrates Synovial Proliferation and Inflammation in Rheumatoid Arthritis through mTOR Signaling

Contact Info

Product

Resources

About